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 Wounds care and management is one of the most basic needs in the medical setting. Burn 
wounds, trauma wounds, pressure ulcers and bedsores are just some of the many types of 
wounds that need to be treated quickly and efficiently. Take for instance pressure ulcers, there at 
least 3 million reported cases of chronic ulcers and bedsores reported in the U.S. each year alone. 
Each ulcer can takes weeks to months to fully heal, leading to extended hospital stays and 
decreased quality of life in patients. Current treatment seeks to protect and keep the wound clean, 
manage cellular exudates, and in general reduce wound area. This is done by packing antibiotic 
gels into the wound bed, which have a bolus drug release profile, and covering the area with 
commercially available bandages. There are many studies documenting bolus drug release 
profiles and their effects on wounds, but what is distinctly absent are studies which investigate 
the effects of continuous drug delivery on wound healing. 
 
 Here it is hypothesized that applying a continuous flow of fresh drugs into the wound bed 
will speed up the often lengthy wound healing process. To examine this hypothesis, human 
umbilical vein endothelial cells (HUVEC) and adult human dermal fibroblasts (HDFa) cell 
culture models were used to mimic the wound healing process. Results were characterized by the 
rate of cell migration and proliferation (wound closure) into a simulated wound channel created 
in the middle of nearly confluent HUVEC and HDFa cell culture models. Both cell types were 
exposed to static or continuous flow conditions with and without drug infused media. For the 
HUVEC cells testing indicates a significant difference between the average rate of closure for 
flow versus no flow conditions (0.0628 versus 0.0232 percent closure per minute, p = 0.00165). 
For the HDFa cells testing indicates a significant difference between the average rate of closure 
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for flow versus no flow conditions (0.0595 versus 0.0392 percent closure per minute, p = 
0.01606). The research suggests that positive growth rate occurs in HDF and HUVEC when 
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Wound Healing Process of Chronic Wounds: 
 Over 3 million Americans are afflicted with pressure ulcers, bedsores, and other related 
wounds each year. They are classified on a scale from 1 to 4, where 1 is redness of skin with 
some pain on contact and 4 is full thickness tissue loss down to the bone [1, 2]. The healing 
process for these types of wounds can often take weeks, and can be very labor intensive for staff 
to treat. The wound healing process in general is composed of five steps hemostasis, 
inflammation, migration, proliferation, and remodeling. The hemostasis phase occurs 
immediately after the initial wound and is indicated by the clotting cascade causing the bleeding 
to stop [3]. Fibrinogen elicits the clotting mechanism and in conjunction with the establishment 
of the fibrin network, resulting in the formation of the clot [4]. The inflammatory phase occurs 
nearly simultaneously with the hemostasis phase and primarily includes the congregation of 
neutrophils at the site of the wound. Also present during this phase is the vasodilation of 
surrounding vessels in an attempt to get blood to the site of the wound. The migration and 
proliferation phases are of the most interest to the wound healing process because they are the 
most easily altered to speed up the wound healing process [3]. 
 
 The migration phase is characterized by the movement of epithelial cells and fibroblasts 
to the wound bed in an attempt to replace damaged or destroyed tissue. Proliferation is initiated 
by the further filling of the wound bed by growing and dividing new cells. Granulation tissue is 
formed as blood and lymph vessels are reestablished. This phase is also characterized by 
thickening of the epithelial layer [5]. These two phases can take anywhere from a few days to 
weeks to complete, which is why shortening these two phases is very important in managing the 
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wound healing process. The final phase is the remodeling phase where connective tissue is 
formed to strengthen the new epithelium. This final phase can take anywhere from a month to a 
year to complete depending on the effectiveness of the administered treatments early on [3].  
 
Current Techniques to Treat Chronic Wounds: 
 The techniques used to treat chronic wounds all seek to accomplish a few things. These 
goals are to manage exudates [6], debridement of the wound [7], protecting the wound from 
infection, and be low maintenance [8, 9]. Clinically there are a few methods used to treat chronic 
ulcers or bedsores, most include a combination of wound dressings and topical gels. The wound 
is typically cleaned with an isotonic saline solution to remove foreign contaminants. Depending 
on the type of wound a variety of pharmaceutical therapies can be administered.  These include 
silver nitrate [10], a silver sulpha-diazine [11, 12], antibiotics, antimycotics [3], or drugs that 
promote angiogenesis and granular tissue growth (e.g., Regranex
TM
) [13]. These different 
treatment modalities require several treatments/day, which can lead to variations in the amount 
of therapeutic used [14, 15]. Another mechanism of treatment used for extreme cases is a tissue 
graft transplant to fill in the affected area [16, 17]. Apligraf is one such example of a skin 
substitute which contains living cells and structural proteins to act as a scaffold for new tissue 
regeneration. One thing all these methods have in common is that when a drug is applied, it has a 
bolus release profile that in no way maintains a constant concentration of the drug being 
delivered to the wound [3, 18]. A more recent method of treatment for wounds is vacuum or 
negative pressure therapy. Vacuum therapy works by pulling exudates out of the wound rather 
than allowing them to merely seep out of the wound resulting in a faster mechanism of action. 
The vacuum therapy also results in a mechanical tension on the underlying tissue which results 
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in dilated arterioles and an increased blood supply to the wound [19, 20]. Vacuum therapy 
treatment is the closest to being called a continuous flow treatment that is currently available. 
The fact that so much research is being thrust into vacuum therapy lends credence to the idea that 
continuous flow will greatly benefit wounds and should be explored.  
 
Continuous Drug Delivery with Novel Knudsen Pump 
 Currently being developed is a pump which is capable of providing continuous 
circulation of fluids without power, using only thermal gradients. Since it doesn’t need a power 
supply, it is able to be made small and would be perfectly suited for wound healing especially 
when incorporated into a bandage or other wound dressing. Theoretically, this pump is able to 
produce flow rate between 0.01 and 0.25 mL/min in a constant fashion based on the thermal 
gradient generated between the skin and the ambient air temperature. The development of this 
device and the introduction of it into the field of medical devices poses new questions about the 
effects of flow on wound healing. Very little research has been conducted into low flow effects 
on healing wounds as well as continuous perfusion of a drug into the wound. The creation of this 
novel device is partially what prompted this investigation. The flow parameters used in testing 
were restricted to those flow rates capable of being generated by the device.   
 
Known Flow Effects on Cells: 
 Some recent experimentation has been conducted to look at the effects of shear stress on 
simulated wound HUVEC cell culture models [21]. One such experiment presheared the cells for 
18 hours at 12 dyn/cm
2
 to obtain alignment of the cells in the direction of the flow field. After 
which they sheared the cells at values of 3, 12, and 20 dyn/cm
2
. Results of testing showed 
increased wound closure at all levels of shear stress over the static conditions. In addition they 
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found that the lower shear stress value 3 dyn/cm
2
 produced a significant effect on wound healing 
over the higher shear stress values [22, 23]. It is important to note that these levels of shear stress 
are radically higher than those capable of being produced by the continuous flow pump described 
above. Another such investigation examined at what levels of shear HUVEC cells began to 
display different cellular adhesion molecules. They found that at shear levels around 8 dyn/cm
2
 
there is a significant upregulation of ICAM-1 and E-selectin, two cellular adhesion molecules 
[24, 25, 26]. At shear stress levels lower than 8 dyn/cm
2
, these effects were not significantly 
altered. This information provides a shear stress threshold at which the HUVEC cells can be 
expected to begin differentiation. There is little to no data regarding flow effects with shear stress 
lower than 3 dyn/cm
2
 on HUVEC cells and there is no data investigating this effect on HDFa 
cells. It would be beneficial to explore the relationship between shear stress lower than 3 
dyn/cm
2 
and the resulting cellular growth rates.  
 
Known Effects of VitaSol on Cells: 
 The effect of VitaSol, an ATP lipid vesicle formulation, on cells has been extensively 
reported in the literature. In one example, VitaSol was tested in a nude mouse wound healing 
model. A small incision was made on the head and covered with a protective bandage soaked 
with the ATP lipid vesicles. When compared to the control treatment it was shown that that 
VitaSol significantly reduced wound area and healed the wound faster. The VitaSol also had a 
marked positive effect on the reepithelialization and granular tissue shown in histological studies 
as well as a significant increase in a produced revascularization growth factor, VEGF [27, 28]. 
Another study used VitaSol in an attempt to speed the wound closure rates in an ischemic rabbit 
ear model. For this investigation the VitaSol was again applied as a drug soaked bandage. The 
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results of this experimentation concluded similar results to the first, in terms of wound closure 
rates the VitaSol significantly reduced to number of days until full healing when compared to a 
saline control [29, 30]. It is important to note the delivery mechanism of the VitaSol treatment. 
For each conducted investigation the delivery method was a bolus profile. A drug soaked 
bandage was applied to the wound and was changed daily. This means a higher concentration of 
the drug will be released initially which will eventually tapper off. It is unknown how the drug 
will behave when applied to a wound at a constant concentration through continuous flow. It is 
expected that the displayed effects would be even greater than those demonstrated by these 
articles. These are just two examples of studies conducted using ATP infused lipid vesicles and 
the effects they are capable of. Intracellular absorption of ATP has also been shown to upregulate 
certain growth factors suspected to assist in the wound healing process [31]. 
 
Purpose of Research: 
 The goal of this research investigation is to characterize the effect of flow conditions on 
several types of cell culture models and assess the potential it has to overcome the previously 
mentioned drawbacks to current wound therapies. Some research has been done to study the 
effects of flow on HUVEC cell culture models as it pertains to wound healing rates, however, all 
research that has been conducted dealt with extremely high flow rates and shear stresses, well 
outside the realm of what the continuous flow device being developed is capable of. Currently 
published research also does not investigate what effects, if any, flow has on HDFa cells. In the 
field of research there is a need to characterize the effects of low flow on HUVEC and HDFa 





Discussion of Model Used: 
 For this investigation HUVEC and HDFa cells were chosen to model the behavior of a 
healing wound. During the wound healing process it is known that fibroblasts play a key role in 
filling the wound bed. This filling of the wound plays a crucial role in the overall recovery time 
as it protects the wound from infections which, if the wound becomes septic slows the wound 
healing substantially. Another crucial aspect of the wound healing process is the 
revascularization and angiogenesis of new blood vessels in to wound area to replace the vessels 
that were destroyed or damaged at the time of the initial wound creation. Reestablishing blood 
flow and a fresh nutrient supply to the wound bed ensures that cells have all the supplements 
they need for optimal growth rates. Reforming this complex network of blood vessels faster 
should in turn allow the rest of the cells to close the wound faster. It is widely accepted that 
HUVEC cells are a suitable cell line to model revascularization which is why they too were 
chosen for this investigation.  
 
Hypotheses: 
 It is hypothesized that an application of continuous flowing media over the cells will 
increase the observed growth rate of HUVEC and HDFa cells over no flow media conditions. It 
is further hypothesized that the flow of media will increase metabolic rates and mitochondrial 
activity in HUVEC and HDFa culture models. Finally, it is hypothesized that adding ATP 
infused lipid vesicles will substantially increase not only the observed growth rates of the cell 







 This section contains specific information regarding the instrumentation used throughout 
the duration of this experimentation. 
Fluorescence Spectrometer: 
 Fluorescent readings were taken using a LS 50B Fluorescence Spectrometer (Perkin 
Elmer, Waltham, MA) using a cuvette with optical path length of 10 mm. Slits for excitation and 
emission beam were set to 15 and 20, respectively.  
Dynamic Light Scattering Detector: 
 DLS measurements used to measure vesicles radius were taken using a Protein Solutions 
DynaPro Titan with Temperature Controlled MicroSampler (Wyatt Technology, Santa Barbara, 
CA) using a cuvette with 10 mm optical path length. Scans were performed at temperatures 37°C 
with a scattering angle of 90
o
. DI water was used as a standard. 
Spectrophotometer: 
 Absorption scans to measure protein and MTT assays were taken using GENESYS 10S 
UV-Vis spectrophotometer (Thermo Scientific, Pittsburgh, PA) using a cuvette with 10 mm 






 Before conducting the primary wound closure rate experiment, smaller verification 
experiments had to be conducted to ensure the proper criteria were met for the main design. Each 
of these verification steps is detailed in the subsections below with a description of the materials 
required to complete the task. 
 
Making the VitaSol: 
 For the purposes of this experimentation, two of the testing groups will be given a dosage 
of ATP such that the cells experience a 0.1 mg/mL working concentration of the drug with a 5 
mmol ATP concentration in HBSS. To make the drug according to these specifications the 
following steps were conducted. To make VitaSol: mix soy phosphatidylcholine 95% (SOYPC, 
Avanti Polar Lipids, Alabaster, Alabama) in solid form and 1, 2-dioleyol-3-trimethyl-
ammonium-propane (DOTAP, Avanti Polar Lipids, Alabaster, Alabama) dissolved in chloroform 
in a weight ratio of 50:1 respectively.  
 
 The lipids were weighed out and mixed together in a 50 mL plastic test tube. Once mixed 
it is necessary to dry off the chloroform from the mixture. To do this nitrogen gas is blown over 
the lipids while gently rotating the test tube to speed up the drying process. Once the lipids 
appear dry the test tube is placed into a vacuum chamber overnight to further remove any traces 
of chloroform.  
 The next day the lipids were rehydrated using a stock solution composed of DI water, 
ATP magnesium salt (5 mM, Avanti Polar Lipids, Alabaster, Alabama), Trizma Base (25 mM, 
Sigma-Aldrich, St. Louis, Missouri), and hanks balance salt solution (HBSS) (9.5 g/L, Sigma-
15 
 
Aldrich, St. Louis, Missouri). To make the stock solution the three solid components were 
weighed out in the proper quantities, added to the correct volume of DI water, and mixed 
thoroughly. 
 Once the stock solution had been created it was added to the lipids along with several 
glass beads. The resulting solution was then vortexed to fully rehydrate the lipids in the stock 
solution. This rehydration process may take anywhere from 20 minutes for small batches to 2 
hours for larger batches of VitaSol. It is important to try to keep the solution at room temperature 
and covered with aluminum foil to limit any light interactions that may occur which can degrade 
the lipid vesicles.  
 After rehydration it was necessary to sonicate the sample to reduce aggregation of the 
lipid vesicles and bring down the average hydrodynamic radius of the particle. Samples were 
sonicated for 10 minutes at a 50% duty cycle (Branson Sonifer, VWR Scientific, Radnor, 
Pennsylvania). The VitaSol solution was then centrifuged for 10 minutes at 2000g to remove any 
titanium contaminants that flaked off from the sonicator probe.  
 After centrifugation the VitaSol was extruded through a 0.1 μm filter using a nitrogen 
cavitation bomb (Parr Instruments, Moline, Illinois). This further refines the average size of the. 
The extrusion process is completed by pressuring a reservoir containing the VitaSol to around 
300 to 600 psi at 40
o
C using a water jacket or circulating water bath. After the extrusion the 
resulting VitaSol solution was ready for use in experimentation, although the size and pH were 
verified first.  
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 The pH was checked to be around 7.4 since this is physiologic conditions. The pH was 
tested by using a calibrated pH probe (Oakton pH Tutor, Cole-Parmer, Vernon Hills, Illinois) 
immersed in the VitaSol solution. To measure the hydrodynamic radius of the lipid vesicles of 
VitaSol, a 50 μL sample was placed in a 450 μL of sample buffer and equilibrated to room 
temperature.  The VitaSol solution was measured using a Protein Solutions Dyna Pro Dynamic 
Light Scattering device. Roughly 60 to 100 unique measurements, taken at a count rate of 5000 
per measurement, were taken from the sample to ensure that the size was around 100-120nm in 
radius with a fairly low poly dispersity index. The sample is considered usable as long as the 
average size is kept less than 150 nm in radius. This is how all VitaSol testing solutions were 
created for the duration of these experiments.  
 
Vesicle Binding By Native Media Proteins: 
 It is known that the proteins in the culture media can have a binding affinity for certain 
substances introduced into the media. In terms of this experimentation the ratio of injected ATP 
lipid vesicles bound by the native media proteins was unknown and needed to be quantified so 
the proper dosage of VitaSol could be given to the cells. This binding ratio was determined 
through a column separation technique. 
 
 The lipid vesicles were labeled with Nile red (Molecular Probes-Invitrogen, Eugene, 
Oregon) dissolved in a solution of 25% dimethyl sulfoxide (DMSO) 75% deionized water, such 
that a final working concentration of 1 mg/mL was achieved [32, 33]. The Nile red stock solution 





environment for 1 hour. This resulted in Nile red dye becoming trapped in the lipid bilayer due to 
hydrophobic interactions between the Nile red molecule and the inner bilayer space.  
 
 The labeled vesicle solution was added to the culture media in a 1:1 ratio. Since two cell 
culture types are going to be used, each required a binding profile to be established. The media 
being tested is the EGM-2 media (Lonza-Clonetics, Basel, Switzerland) for the HUVEC cells 
and M-106 media (Gibco-Cascade Biologics, Eugene, Oregon) for the HDFa cells. Once 
combined the testing sample was placed in the incubator at 37
o
C and left to sit overnight (at least 
12 hours).  In order to separate the unbound lipids from the media proteins, a Sepharose-2B 
(Sigma-Aldrich, St. Louis, Missouri) packing agent was used in a column length of 40 cm [34]. 
When pouring the column the Sepharose gel was diluted in a small amount of the running buffer 
in a ratio of 4:1 respectively [35]. A depiction of the setup is shown in Appendix I Photo 1. In 
order to test the media samples, 1 mL of the lipid vesicle/media combination was taken and 
loaded into the gel column. As the sample began to flush through the column, collection samples 
were collected in 1 mL intervals for further analysis. Collection of the samples was stopped 5 
mL after the media band was no longer visible which made sure the entire sample had been 
collected. Throughout the duration of the experiment roughly 25 mL of samples was collected 
for the EGM-2 media and 30 mL of samples was collected for the M-106 media. It was decided 
that an N=3 would be required to generate an accurate assessment of the ratio of bound lipid 
vesicles, so for each media type three unique media sample were run.  
  
 Once these samples were collected it was necessary to run both a fluorescence 
measurement and a BCA assay measurement on them. Fluorescence measurements were 
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obtained using a luminescent spectrometer (Perkin-Elmer, Model# LS50B) and reading the 
fluorescence measurement at an excitation wavelength of 533 nm and an emission wavelength of 
544 nm. The BCA assay was conducted using the test tube method. The test tube method 
required 0.1 mL of each unknown sample to be pipetted into individual glass test tubes. 2 mL of 
the working reagent was then added to each sample. The working reagent was created by mixing 
together in a 50:1 ratio reagent A to reagent B respectively. Once the working reagent had been 
added to the test sample, each of the glass test tubes were covered and placed in the incubator at 
37
o
C for 30 minutes. Each sample, after incubation, was read by a spectrophotometer (Thermo-
Scientific, Model# Genesys 10-S) at a wavelength of 562 nm.  
 
 With this information known one can now estimate the sum of the area under the lipid 
fluorescence curve and compare that to the sum of the area under the protein bound lipid curves. 
Since the exact equation of the curve is unknown a trapezoidal approximation was conducted to 
get as close to the actual area as possible. The trapezoidal approximation for each of the media 
samples can be found in Appendix II Chart 1 for the EGM-2 media and Chart 2 for the M-106 
media. Looking at the results it is clear that in both media conditions a little over half of the 
injected lipid vesicles are bound by the native proteins, meaning that for the desired 0.1 mg/mL 
working concentration to be attained 0.2 mg/mL must be injected into the culture media. This 
number the guidance for how much of the lipid vesicle mixture should be added to the media in 






Flow Field Verification: 
 Since the primary observation of these experiments is the rate change as it pertains to 
flow, needless to say the flow characteristics the cells are experiencing are quite important. Flow 
rate, shear stress, and type of flow all needed to be defined and were determined via dye 
injection analysis [36]. For this verification dye was injected into the DI water being pumped 
through the system. The trajectory of the dye particles was observed under the microscope and 
caught on the camera system by taking video. The video was then analyzed in slow motion to 
obtain the flow velocity of the particles moving through the system. Knowing the velocity the 
shear stress could then be calculated as well as the Reynolds number to determine the type of 
flow. Also in the video the particles were tracked to see if any types of vortexing or swirling 
were present which would tend to indicate a more turbulent flow. Example photographs of how 
this verification were conducted are shown below in Appendix I Photo 6-8 
 
 
Wound Closure Rate Experiments: 
 HUVEC and HDFa Culture and Passage 
For this experimentation all cellular samples needed to complete the testing sets were cultured 
prior to testing and frozen back in cryopreservation. To do this 1
o
 HUVEC and 1
o
 HDFa cells 
(Lonza, Walkersville, Maryland) were clonally expanded to achieve the desired passage number 
(4
 o
). Once the cells reached the desired passage number they were divided out into individual 
vials containing the exact number of cells required to plate the specialized RC-40 glass bottom 
dishes (Wilco Wells, Amsterdam, Netherlands) used with the DH-40i microincubation system 
(Warner Instruments, Hamden, Connecticut) used during testing. A depiction of the incubation 
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system can be found in Appendix I Photo 2. Each dish should be optimally plated with 50,000 
cells so this was the number chosen to cryopreserve the cells at. This meant that all testing 
samples were kept at the exact same passage number, and from the same cultured cell line.  
 
Setting Up the Microincubation System: 
 The microincubation system was specifically designed to culture cells under continuous 
view from a microscope. For this reason thermal controls and heating elements as well as media 
pumping lines all had to be condensed to fit on a standard microscope stage. The DH-40i system 
has flow ports built in so it was easy enough to connect sterile tubing lines to the incubation 
system, run them through a dual peristaltic pump, one capable of both pumping in fluid and 
pulling it back out, and finally connect the tubing to a sterile media reservoir. The heating 
elements are also built into the incubation system and are designed to be able to maintain the 
ideal temperature of 37
o
C needed to culture the cells. This ability to maintain the temperature of 
the system was verified using a handheld IR thermometer as well as a thermocouple. This 
verification step is displayed in Appendix I Photo 3. Prior to each experiment the tubing 
transporting the media as well as the cover dish on the microincubation system were autoclaved 
to cut down on the risk of infection. A photo of the final setup can be found in Appendix I Photo 
4. 
 
Preparing and Testing Samples: 
 Once the culturing system was functional, testing could begin, however, since the culture 
dishes were all glass bottom dishes it was necessary to gelatinize the dishes prior to plating the 
cells in order to initiate adhesion sites. This was done by allowing the glass bottom dishes to 
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incubate overnight with a 0.1 % gelatin coating. The 0.1 % gelatin solution was created by taking 
0.1 g of the gelatin powder (Sigma Aldrich, St. Louis, MO) and adding that to 100 mL of DI 
water. The solution was then sterile filtered under the laminar flow hood, aliquoted into sterile 
test tubes, and stored in the 4
o
C refrigerator throughout the duration of experimentation until it 
was needed for each sample. Each culture dish was prepped with this gelatin solution before 
being plated with either the HUVEC of HDFa cells.  
 
 Once plated the cells were allowed to become nearly confluent at which time a 1ml 
sterile pipette tip was used to scratch a simulated wound channel directly in the middle of the 
wound culture dish. The resultant wound channel should be roughly 1.5 mm to 2 mm in width 
with clearly defined borders. Once the channel had been created, the culture dish was placed 
inside the microincubation system in a sterile environment under the laminar flow hood, after 
which the chamber was sealed to preserve the sterile environment. Once sealed, the setup was 
taken to the microscope and connected to both the peristaltic pump and the DC power supply. To 
maintain physiologic pH, a 5 mM concentration of HEPES was added to the culture media for 
each sample. Once fully connected, initial measurements of the wound channel were taken and 
subsequent photos were taken every 15 minutes to track the closure of the wound. Samples were 
allowed to run for approximately 15 hours, giving plenty of data to track wound closure rates 
over time. After each sample had been tested the culture dish was removed, sterilized, and 
disposed of. In addition the microincubation system was cleaned and prepared for the next test 




 Roughly five samples needed to be run in each of the four testing groups in order to 
determine significance. The static flow testing group with regular media and the static flow 
testing group with VitaSol doped media were batch processed to speed up the data collection 
rate. This means that all five of the samples were run at the same time while taking photos at 
discrete measurements manually. The samples in the flow testing group with regular media and 
the flow testing group with VitaSol doped media were tested individually using the camera 
system and the microincubation stage described above. It is important to note that five samples in 
each of the testing groups were run for both the HUVEC and the fibroblast cell culture models. 
This is how samples were run to obtain the rate of wound closure measurements. 
 
 Data was obtained through a Nikon D90 camera mounted to the microscope imaging the 
cells at 10x magnification. This way the cells could be monitored and their growth progress 
tracked over time. As mentioned earlier the static flow cells were batch processed, meaning that 
six samples were grown and imaged at the same time. The cell chambers were each marked so 
that the same location in the wound bed could be imaged each and every time ensuring that the 
data is accurate. For the static flow conditions, images were taken every 6-8 hours excluding 
overnight. During imaging, two unique locations in each cell culturing dish were photographed, 
which made sure that an average wound distance could be obtained for each sample. For the flow 
conditions, each sample had to run individually since it had to be placed in the special remote 
culturing stage. For this reason only one unique location could be imaged for each sample since 
the sample couldn’t be moved once placed in the culturing stage. However, unlike the static flow 
conditions, the images could be taken at a much closer interval, in this case every 15 minutes 
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essentially creating a video as the cells fill in the wound bed. In all cases, no matter how the 
photos were taken, all photos were analyzed the same way.  
  
 Using the ImageJ software, freely downloaded from the NIH website, the wound bed gap 
distance was measured and recorded in an excel spreadsheet. Before using the ImageJ software 
the scale first had to be calibrated before measurements could be obtained. To calibrate the scale, 
a photo of a 2 mm scale bar, shown below in Appendix I Photo 5, taken at the same 
magnification of the cells in the experiment (10x) was used. Once the scale had been calibrated 
the images were analyzed. For each image three unique distance measurements were obtained, 
one on the far left, one in the center, and one on the far right. The wound boundary on each side 
was identified as best as possible and this became the start and the finish of the distance 
measurements. A depiction of how these three measurements were taken is shown below in 
Appendix I Photo 9. After obtaining the distance measurements, they were all converted into a 
percent representing the closure when compared to the original wound channel distance. By 
converting these measurements to a percent it eliminates any bias caused by different initial 
wound channel lengths which greatly reduces the expressed standard deviation. 
 
 
MTT Assay of Cells After Imaging: 
 After the imaging sequence had been completed an MTT assay was run on a select 
number of samples from each testing group. While an MTT assay is normally used to determine 
the number of metabolically active cells in a culture dish, it can also be used to assess the degree 
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of mitochondrial activity exhibited by the sample if the amount of cells remains constant from 
sample to sample.  
 
 To conduct the MTT assay the reagent solutions were created according to the Vybrant 
recommended protocol [37]. A 12 mM MTT stock solution was created by adding 1 mL of 
sterile PBS to one 5 mg vial of MTT Component A (Invitrogen-Molecular Probes, Eugene, 
Oregon). A second reagent solution is created by adding 10 mL of 0.01 M HCl to one tube 
containing 1 g of SDS Component B (Invitrogen-Molecular Probes, Eugene, Oregon) contained 
in the same kit as the MTT component.  
 
 Since the culture dished used in this experimentation differ in surface area from the ones 
used in the Vybrant MTT assay protocol the amounts of each reagent used had to be scaled 
accordingly. It was determined that a scaling factor of 9 should be used on all values discussed in 
the Vybrant protocol. This means that to begin the MTT assay all media was removed from the 
culture dishes and was replaced with 900 μL of fresh media. At this point 90 μL of the MTT 
reagent solution to each culture dish and were placed in the incubator at 37
o
C for 4 hours. After 
the incubation period was complete the samples were removed and 900 μL of the SDS reagent 
solution was added to them and mixed thoroughly with a pipette. After mixing the samples were 
placed back in the incubator at 37
o
C for another 4 hours. After this final incubation period the 
samples were removed, mixed again, and tested for absorbance measurements at 570 nm using a 





Vesicle Binding by Native Media Proteins: 
 With this information generated from this experiment one can now estimate the sum of 
the area under the lipid fluorescence curve and compare that to the sum of the area under the 
protein bound lipid curves. Since the exact equation of the curve is unknown, a trapezoidal 
approximation was conducted to get as close to the actual area as possible. The trapezoidal 
approximation for each of the media samples can be found in Appendix II Chart 1 for the EGM-
2 media and Chart 2 for the M-106 media. A summarized chart of this data is shown below. 
 
EGM-2 


















1 59.03% 40.97% 
 
1 58.16% 41.84% 
2 57.63% 42.37% 
 
2 63.79% 36.21% 
3 54.60% 45.40% 
 
3 60.13% 39.87% 
       Avg 57.08% 42.92% 
 
Avg 60.69% 39.31% 
STDEV  2.26% 2.26% 
 
STDEV 2.85% 2.85% 
       Chart 7: Averages and standard deviations for the ratio of lipid vesicles bound to media proteins 
for each media type. 
 
 Looking at the results it is clear that in both media conditions a little over half of the 
injected lipid vesicles are bound by the native proteins, meaning that for the desired 0.1 mg/mL 
working concentration to be attained, 0.244 mg/mL must be injected into the EGM-2 culture 
media and 0.254 mg/mL must be injected into the M-106 culture media. This number the 
guidance for how much of the lipid vesicle mixture should be added to the media in future 
experiments in order to achieve the correct working concentration.  
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Flow Field Verification: 
 
 Analyzing the video in slow motion produced a flow velocity of v=2.97x10
-4
 m/s, a rate 
consistent with the theoretical output of the continuous flow drug delivery device. Using the 
equation: 
   Q=vbh  
where v is the flow velocity and b and h are the dimensions of the culture dish, one can calculate 
the flow rate of the system. This turns out to be Q=0.267 mL/min, again consistent with the 
theoretical output of the drug delivery device. Using this flow rate one can plug it into the 
equation for shear stress: 
   T=(6Qu)/(bh
2
)  
where u is the viscosity of the culture media. Plugging all terms into this equation yields a shear 




, which is well below the target shear stress of 
0.3N/m
2
 meaning that these conditions won’t influence differentiation of the HUVEC cells. One 
final bit of validation was to determine the Reynolds number with regards to the type of flow. 
The equation used in this case is: 
   Re=ρvl/u  
where ρ is the density of the media, v is the velocity, and u is the viscosity over the respective 
length l. Substituting these values gives a Reynolds number of 1.612. A Reynolds number of less 
than 2300 tends to indicate laminar flow. In this case laminar flow makes sense because the 








Wound Closure Rate: 
 It is important to note that this system required many iterations in order to integrate all 
the many functional components of the experimental system. For example, the media reservoir 
required a specially designed heating system to keep the cells exposed to 37°C media. Other 
challenges included modifications to the height adjustments to the flow inlet or outlet to prevent 
loss of culture media, random software crashes due to the massive amounts of data 
accumulated/experiments, and issues with microscope failure where the bulb burned out from 
prolonged use.  
 Results from the cellular model of wound closure are expressed as a rate measurement of 
the changes in area over time. In addition an MTT assay on a portion of the samples in each of 
the testing groups was analyzed to measure cell proliferation and mitochondrial activity. In 
addition to these quantitative measurements, the photo sets were carefully inspected in an 
attempt to gage the mechanism of cellular wound closure. In this case the goal was to determine 
if cell proliferation, migration, or a combination of both was the primary mode of closure. No 
physical numbers were generated in closure mechanism analysis; instead it was more of a 
subjective investigation to see if there was a difference. In analyzing the data, a significant 
difference in values between the sets was determined if the p-value from the student’s t test was 
less than 0.05. Before the student’s t test was conducted an f test first had to be conducted to 







Cellular Model of Wound Closure Data: 
 Looking at the data generated from the Image J measurements and averaging them 
together generates the graphs shown in Figures 13-15 for the HUVEC cells and Figures 16-18 
for the HDFA cells.  
 
Figure 13: Comparison between HUVEC Flow and No Flow conditions. HUVEC Flow showed 
significantly faster closure rates than HUVEC No Flow (p=0.00165). 
 
 To prove the first hypothesis whether low flow influences cellular wound closure rates, 
the data was examined between the HUVEC Flow and No Flow conditions. It was shown that 
HUVEC Flow had an average rate of closure of 0.0628 percent per minute whereas the HUVEC 
No Flow had an average rate of closure of 0.0232. This resulted in a significant difference 
y = -0.0147x + 101.49 
R² = 0.9688 
y = -0.0616x + 98.597 






























HUVEC Flow Vs. No Flow 
HUVEC No Flow HUVEC Flow 
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(p=0.00165) between Flow and No Flow conditions thus proving the initial hypothesis that low 
flow rate can accelerate wound closure at least in the HUVEC cell culture model.  
 
Figure 14: Comparison between HUVEC VitaSol and No VitaSol conditions when subjected to a 
flow environment. There was no observed difference between the closure rates for the HUVEC 
VitaSol and No VitaSol testing groups (p=0.3566). 
 
 To prove the secondary hypothesis whether VitaSol influences the wound closure rate, 
the data was examined between the HUVEC VitaSol and No VitaSol conditions when subjected 
to a flow environment. It was shown that HUVEC VitaSol had an average rate of closure of 
0.0730 percent per minute whereas the HUVEC No VitaSol had an average rate of closure of 
0.0628. This did not result in a significant difference (p=0.3566) between VitaSol and No 
y = -0.0762x + 98.335 
R² = 0.9898 
y = -0.0616x + 98.597 






























HUVEC Vitasol Vs. No Vitasol Under Flow 
Conditions 
HUVEC Vitasol HUVEC No Vitasol 
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VitaSol conditions thus suggesting that the secondary hypothesis, that adding VitaSol can 
accelerate wound closure, may not be true. 
 
Figure 15: Comparison between all HUVEC testing groups. There was no observed difference 
between any of the VitaSol testing groups (p=0.3566 and 0.4080 for Flow and No Flow 
conditions respectively). There was a significant difference between the Flow and No Flow 
testing groups (p=0.00165 and 0.00980 with and without VitaSol respectively). 
 
 The raw data used to generate these graphs can be found in Appendix II Chart 3 for the 
HUVEC cells. Taking the closure measurements one can calculate the rate of closure between 
each step. Doing so yields the data found in Appendix II Chart 5 for the HUVEC cells. The 
summarized averages and standard deviations for each of the testing groups are shown in the 
tables below. 
 
y = -0.0147x + 101.49 
R² = 0.9688 
y = -0.0167x + 96.38 
R² = 0.9617 
y = -0.0616x + 98.597 
R² = 0.9932 
y = -0.0762x + 98.335 







































Huvec Control 6 0.0232 0.0122 
Huvec 0.1 mg/mL VitaSol 6 0.0170 0.0105 
Huvec 90 Degree Flow 5 0.0628 0.0168 
Huvec Flow 0.1mg/mL 
VitaSol 








Huvec 90 Degree 
Flow 
Huvec Control - - - 
Huvec 0.1mg/mL VitaSol 0.4080 - - 
Huvec 90 Degree Flow 0.0016 1.024E-06 - 
Huvec Flow 0.1mg/mL 
VitaSol 
0.0012 0.0098 0.3566 
 
Chart 8: Averages and standard deviations for HUVEC cell rate of closure as well as p-values 






Figure 16: Comparison between HDFa Flow and No Flow conditions. HDFa Flow showed 
significantly faster closure rates than HDFa No Flow (p=0.01606). 
 To prove the first hypothesis whether low flow influences cellular wound closure rates, 
the data was examined between the HDFa Flow and No Flow conditions. It was shown that 
HDFa Flow had an average rate of closure of 0.0595 percent per minute whereas the HUVEC No 
Flow had an average rate of closure of 0.0392. This resulted in a significant difference 
(p=0.01606) between Flow and No Flow conditions thus conclusively proving the initial 
hypothesis that low flow rate can accelerate wound closure in both the HUVEC and HDFa cell 
culture models. 
 
y = -0.0616x + 98.597 
R² = 0.9932 
y = -0.0395x + 98.367 






























HDFa Flow Vs. No Flow 




Figure 17:  Comparison between HDFa VitaSol and No VitaSol conditions when subjected to a 
flow environment. There was no observed difference between the closure rates for the HDFa 
VitaSol and No VitaSol testing groups (p=0.3314). 
 
 To prove the secondary hypothesis whether VitaSol influences the wound closure rate, 
the data was examined between the HDFa VitaSol and No VitaSol conditions when subjected to 
a flow environment. It was shown that HDFa VitaSol had an average rate of closure of 0.0661 
percent per minute whereas the HDFa No VitaSol had an average rate of closure of 0.0595. This 
did not result in a significant difference (p=0.3314) between VitaSol and No VitaSol conditions 
further suggesting that the secondary hypothesis, that adding VitaSol can accelerate wound 
closure, may not be true since this was the case in both HUVEC and HDFa culture models. 
 
y = -0.0636x + 98.38 
R² = 0.9913 
y = -0.0639x + 100.89 






























HDFa Vitasol Vs. No Vitasol Under Flow 
Conditions 




Figure 18: Comparison between all HDFa testing groups. There was no observed difference 
between any of the VitaSol testing groups (p=0.0794 and 0.3314 for Flow and No Flow 
conditions respectively). There was a significant difference between the Flow and No Flow 
testing groups (p=0.01606 and 0.00386 with and without VitaSol respectively). 
 
 The raw data used to generate these graphs can be found in Appendix II Chart 4 for the 
HDFa cells. Taking the closure measurements one can calculate the rate of closure between each 
step. Doing so yields the data found in Appendix II Chart 6 for the HDFa cells. The summarized 









y = -0.039x + 98.237 
R² = 0.9973 
y = -0.0368x + 97.945 
R² = 0.991 
y = -0.0639x + 100.89 
R² = 0.9945 
y = -0.0636x + 98.38 










































HDFa Control 5 0.0392 0.0118 
HDFa 0.1mg/mL VitaSol 6 0.0156 0.0579 
HDFa 90 Degree Flow 5 0.0595 0.0210 
HDFa Flow 0.1mg/mL 
VitaSol 








HDFa 90 Degree 
Flow 
HDFa Control - - - 
HDFa 0.1mg/mL VitaSol 0.0794 - - 
HDFa 90 Degree Flow 0.0160 0.0035 - 
HDFa Flow 0.1mg/mL 
VitaSol 0.0058 0.0038 0.3314 
 
Chart 9: Averages and standard deviations for HDFa cell rate of closure as well as p-values 
between testing groups. 
 
 To check for statistical significance an f test first had to be run comparing each of the test 
groups to one another. The f test determines if the variance between the groups is equal or 
unequal and based on this result, the proper t test can be chosen. Running the appropriate t test 
for each comparison yields the full statistical tables seen in Appendix 2 Tables 1 through 12. 
Representative photos of each of the testing groups can be found in Appendix III. 
 
MTT Mitochondrial Activity Assay: 
 As mentioned previously an MTT assay was attempted on select samples within each of 
the testing groups in order to try to gauge the level of mitochondrial activity displayed between 





Figure 19: MTT Assay comparison between Flow and No Flow conditions. No significant 
difference was observed between Flow and No Flow for both HUVEC and HDFa culture models 
(p=0.3265 and 0.1950 respectively). 
 
 To prove the tertiary hypothesis, whether low flow rates induce higher mitochondrial 
activity, the data was examined between the HUVEC and HDFa Flow and No Flow conditions. 
It was shown that HUVEC Flow had an average absorbance 0.0328 whereas the HUVEC No 
Flow had an average absorbance of 0.0316. The HDFA Flow had an average absorbance 0.0325 
whereas the HDFa No Flow had an average absorbance of 0.0311. This did not result in a 
significant difference (p=0.3265 and 0.1950) in mitochondrial activity for either HUVEC of 
HDFa cultures respectively, as it pertains to flow. This suggests that the tertiary hypothesis may 




















MTT Assay Flow Vs. No Flow 
Huvec Control 
Huvec 90 Degree Flow 
HDFa Control 




Figure 20: MTT Assay comparison between VitaSol and No VitaSol conditions. No significant 
difference was observed between VitaSol and No VitaSol for both HUVEC and HDFa culture 
models (p=0.5947 and 0.4156 respectively). 
 
 To prove the tertiary hypothesis, whether the addition of VitaSol induces higher 
mitochondrial activity, the data was examined between the HUVEC and HDFa VitaSol and No 
VitaSol conditions. It was shown that HUVEC VitaSol had an average absorbance 0.0326 
whereas the HUVEC No VitaSol had an average absorbance of 0.0328. The HDFA VitaSol had 
an average absorbance 0.0327 whereas the HDFa No VitaSol had an average absorbance of 
0.0325. This did not result in a significant difference (p=0.5947 and 0.4156) in mitochondrial 
activity for either HUVEC of HDFa cultures respectively, as it pertains to the addition of 
VitaSol. This suggests that the tertiary hypothesis may not be true since this was the case in both 
















MTT Assay Vitasol Vs. No Vitasol 
Under Flow Conditions 
Huvec 90 Degree Flow 
Huvec Flow 0.1mg/mL 
Vitasol 
HDFa 90 Degree Flow 





Figure 21: MTT Assay comparison between all testing groups for both HUVEC and HDFa 
culture models. There was no observed difference between any of the testing groups on any level 
for either the HUVEC of HDFa cultures.  
 
  To check for statistical significance an f test first had to be run comparing each of 
the test groups to one another. The f test determines if the variance between the groups is equal 
or unequal and based on this result, the proper t test can be chosen. Running the appropriate t test 
for each comparison yields the full statistical tables seen in Appendix 2 Tables 13 through 24. A 







Huvec 90 Degree 
Flow 
Huvec Control - - - 
Huvec 0.1mg/mL VitaSol 0.8212 - - 
Huvec 90 Degree Flow 0.3265 0.4973 - 
Huvec Flow 0.1mg/mL 
VitaSol 











































HDFa 90 Degree 
Flow 
HDFa Control - - - 
HDFa 0.1mg/mL VitaSol 0.6284 - - 
HDFa 90 Degree Flow 0.1950 0.4963 - 
HDFa Flow 0.1mg/mL 
VitaSol 
0.1716 0.4156 0.8264 
 






Wound Closure Rate Data: 
 Looking at the data generated from the wound closure experiments a few things became 
evident. First and foremost, it seems that the primary hypothesis was proven true. A continuous 
flow of media over the cells does promote higher rates of growth and closure of the wound. This 
is demonstrated by the p values less than 0.05 for all comparisons between the flow test groups 
and the static test groups. Comparing the results of this experimentation to the known flow 
effects on cells the data seems to coincide. While previous experiments used higher flow rates 
than those used in this experimentation it appears that the same effects, accelerated growth rates, 
are prevalent in both cases [22]. This means that when such a device is created, capable of 
sustaining the flow of a drug, such as VitaSol, over a wound bed, it is expected that full closure 
and healing of the wound would be expedited. By speeding up the wound healing process for 
chronic ulcers or bedsores, which often take weeks of recuperation in a hospital, one could 
expect to shorten these lengthy often uncomfortable stays, thus enhancing the quality of life for 
many patients. 
 
 The secondary hypothesis in this investigation was far less definitive after all the results 
had come in. The original intent was to demonstrate that by adding a drug to the circulating 
media, this too will have a positive effect on the growth rate of the cells in culture. What was 
seen from the data was that the VitaSol had no effect whatsoever on either of the cell culture 
models. Comparing these results to the known effects of VitaSol on the cells they do not match 
up. Previous experimentation saw profound effects on cellular growth rates when VitaSol was 
added whereas in this experimentation no difference was observed. The reason for this lack of 
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effect can’t be definitively proven, but after a reexamination of the model used in this testing 
method the likely reason is that the cells were grown under normal oxygen conditions. This is 
further backed up by the fact that previous testing by other labs did in fact culture the cells under 
hypoxic conditions whereas for this experimentation the cells were cultured under normoxia 
conditions [27]. Under normal oxygen conditions the cells will produce adequate amounts of 
ATP required for sustained growth. Since ATP is the functional aspect of the VitaSol treatment 
given to the cells it would be treated as excess and disposed of by the cells. The result of this 
being that the overall growth rates between the cells given the VitaSol infused media and those 
given the standard media remains the same. Given the proper model a difference might be able to 
be gleaned from the data. Clinically it is expected that VitaSol will accelerate healing rates since 
this aspect has been definitively proven in bolus therapy just not yet so in continuously applied 
therapy. 
 
MTT Assay Data: 
 The data generated from the MTT assay was less conclusive. While the data itself is 
reliable and accurate it doesn’t show any statistically significant differences in mitochondrial 
activity between the testing groups. The simple explanation for this lack of significance is the 
shortage of cells being tested with each run of the MTT assay. When creating the calibration 
curve for the number of cells and the absorbance measurements they generate, one of the lowest 
values of cells used is 50,000 while one of the upper values is 1,000,000 cells. The number of 
cells able to be grown in micro incubation dishes used in the experimentation is roughly 100,000 
cells at a max. The actual amount of cells contained in these dishes during experimentation was 
roughly 75,000 based on cell counts using a hemocytometer. This 75,000 falls at the very low 
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end of the calibration curve And could have contributed to the lack of differences noted here. It 
is suggested that future experimentation in this area use greater than 75,000 used hereto 
potentially detect significant differences between groups. It seems that the cells experiencing 
flow tended to have higher absorbance measurements than the static conditions, 0.0328 
compared to 0.0316 for the HUVEC cells and 0.0325 compared to 0.0311 for the HDFa cells,  
 
Closure Mechanism Analysis: 
 This method of analysis, as mentioned earlier was purely subjective. Looking at the static 
flow samples the primary wound closure mechanism was proliferation of the cells into the 
simulated wound channel. While there was some migration of the cells, as they do naturally, the 
migration that was seen was parallel to the wound channel and not into the wound. An example 
of this is shown in Figure 7 below. With the low flow samples the primary wound closure 
mechanism was a combination of proliferation and migration into the wound channel. It seems 
that the flow directed the movement of the cells into the channel where they then began to 
proliferate. An example of this is shown in Figure 8 below. In terms of wound healing in vivo, 
migration of HUVEC cells into the wound could play an important role in their role in 
neovascularization of the wound, which could speed the healing process. Migration of fibroblasts 
into the wound is very important in laying down, extracellular matrix, increasing cellular 
proliferation, and filling the wound are to prevent infection. In conclusion migration of the cells, 
guided by the flow conditions expected to be produced from this device, will expedite the wound 




Figure 7: HUVEC cells in static conditions. Note high cell density on wound borders with some 
lone migratory cells in the wound channel. 
 
Figure 8: HUVEC cells in flow conditions. Note the medium cell density on the wound borders 




 After spending time conducting these experiments it is evident that there is additional 
experimentation which can be conducted to further enhance the conclusions drawn from this 
experimental investigation. The first and foremost is modifying the model in order to show a 
difference between the cells given the VitaSol supplemented media and those given the standard 
media formulation. As mentioned briefly above in the discussion section, there was no 
significant difference between the drug loaded media and the no drug loaded media when there 
probably should have been. After much deliberation, this is thought to be the cause of the normal 
oxygen conditions the cells were introduced to. In a normal oxygen environment the cells are 
able to produce as much ATP as they need, which is the primary active molecule in the VitaSol. 
Therefore any ATP delivered as a result of the VitaSol would be treated as excess by the cells 
and would be discarded from the cells if it is even absorbed at all. It is therefore the 
recommendation to repeat these experiments in a hypoxic environment where the cells are ATP 
deprived, if this is the case then there should be a displayed difference between the VitaSol 
samples and the regular media samples. Retesting the samples under hypoxic conditions would 
probably also more accurately mimic in vivo conditions in a wound, which is often oxygen 
deprived.  
 
 A second recommendation would be to retest the flow samples at different flow rates. 
While this experimentation did show that flow has a significant effect in the rate of wound 
closure it is unknown if the flow used in this investigation optimizes the rate of closure. For this 
reason it would be desirable to attempt to maximize the rate of wound healing by testing at a 
flow rate higher and lower than the one used in this experimentation and see if this makes a 
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difference. It is fairly well documented that high flow rates accompanied with relatively higher 
shear stresses enhances HUVEC cell growth rates especially when the cells are exposed to shear 
stress prior to testing. There is very little documentation regarding what happens to the cells at 
low flow rates with nearly negligible shear stresses, which is why further research into this area 
is recommended.  
 
 A final recommendation would be to test whether flow directionality has a significant 
impact on the rates of wound closure. For this experimentation a perpendicular flow to the 
channel was chosen because that is what the literature precedent used, however, considering the 
nature of a wound bed which is more radial it would be more realistic to test a variety of angles 
of flow. It is theorized that a parallel angle of flow in comparison to the wound channel wouldn’t 
direct the cells into the wound channel to the extent that the perpendicular flow did thus reducing 
the rate of closure. However, since there is still the constant circulating of fresh media with the 
removal of metabolytes would still lead to a significant difference in the rate of growth over the 






 Based on the results from the previously discussed experiments a few things can be 
concluded. One such thing was that a flow rate, even a very low rate, such as the one used in this 
experimentation, promotes cellular growth rates in both the HUVEC and the HDFa cell culture 
models. This enhanced rate should translate to faster filling of the wound bed as well as the faster 
revascularization of the wound bed. Another thing concluded from this round of experimentation 
is that the VitaSol did not have any effect on the growth rate, although likely for the reasons 
discussed above. In a similar fashion the MTT assay also could not display statistically 
significant results because the number of cells used in the assay was too low to display a 
difference in the metabolic rates. Overall, even with some aspects of this investigation being 
inconclusive, the experimentation was still a success as it proved the primary hypothesis. Despite 
the setbacks exhibited during this investigation, the results can still be used as a reliable predicate 
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Appendix I: Experimental Setup Photos 
 
Photo 1: Gel Filtration Column Setup with Extra Running Buffer Reservoir Attached 
Additional Running Buffer Reservoir 
Running Buffer Layer 
Sample Loading Point 
Packed Gel Layer 





Photo 2: DH-40i Microincubation System with labeled flow inlets and outlets designed to supply 
















DC Power Supply 
Thermal Probe 





Photo 4: Complete Cell Culturing System with attached peristaltic pump facilitating the flow of 
media, DC Power supply to maintain physiologic growing temperatures, and attached camera 
system for data collection. 
 
 
Photo 5: 2mm Scale Bar Imaged at 10x used to calibrate the ImageJ software. 
Peristaltic Pump 
Media Reservoir 
DC Power Supply 
Incubation System 
Microscope with Attached 




Photo 6: Image of Particle Tracking Time 1 
 
 
Photo 7: Image of Particle Tracking Time 2 
Tracked Particle Time 1 





Photo 8: Image of Particle Tracking Time 3 
 
 
Photo 9: Depiction of how the distance measurements were taken from each photo. 
Arrows Represent 
Measurements Taken in ImageJ 









































































































































































































































































































EGM-2 Sample 1 
  
EGM-2 Sample 2 
  
EGM-2 Sample 3 
  
 
Area under curve 
  
Area under curve 
  














1 6.3875 5.748 
 
1 1.52 7.607 
 
1 4.244 4.2815 
 2 19.261 11.1135 
 
2 7.271 13.621 
 
2 16.6405 9.81 
 3 16.743 10.297 
 
3 23.2995 14.997 
 
3 19.323 10.6615 
 4 5.236 9.384 
 
4 25.6845 15.411 
 
































 Total 47.6275 68.609 116.2365 Total 67.5965 91.9335 159.53 Total 49.292 59.2755 108.5675 
            Percent Vesicle Bound= 0.590253 Percent Vesicle Bound= 0.576277 Percent Vesicle Bound= 0.545978 
Percent Vesicle Free= 0.409747 Percent Vesicle Free= 0.423723 Percent Vesicle Free= 0.454022 
            
      
Bound Free 
    
     
Avg 0.570836 0.429164 
    
     
STDEV 0.022633 0.022633 















M-106 Sample 1 
  
M-106 Sample 2 
  
M-106 Sample 3 
  
 
Area under curve 
  
Area under curve 
  














1 8.8245 3.723 
 
1 4.568 5.9105 
 
1 4.8755 4.9335 
 2 18.716 5.0485 
 
2 12.8565 8.8015 
 
2 13.5895 7.78 
 3 14.6165 5.8655 
 
3 20.7435 9.94 
 
3 21.6365 9.4985 
 4 6.851 5.1365 
 
4 18.0495 9.526 
 
4 19.9465 9.165 
 5 4.103 4.792 
 
5 9.838 9.9285 
 





6 5.808 10.402 
 























































































































         Total 53.111 73.83 126.941 
        
            Percent Vesicle Bound= 0.581609 Percent Vesicle Bound= 0.637868 Percent Vesicle Bound= 0.601338 
Percent Vesicle Free= 0.418391 Percent Vesicle Free= 0.362132 Percent Vesicle Free= 0.398662 
            
     
Bound Free 
     
    
Avg 0.606938 0.393062 
     
    
STDEV 0.028545 0.028545 















0 100 100 100 100 
180 - - 87.08283323 82.66307058 
360 - - 74.66724515 69.81484197 
540 - - 64.52112872 58.55846844 
720 - - 55.85032968 
 
1250 83.26424961 75.13798662 
  
1580 80.26479179 66.75377326 
  
2855 63.42235514 55.39735261 
  
3130 50.60951082 51.58012993 
  4220 33.27561782 30.44741855 
  4490 21.03643073 24.9938944 
  





   
Chart 3: Data Used to Generate Wound Closure Curves for the HUVEC Cells 
 
 











0 100 100 100 100 
180 - - 88.49115244 86.43940776 
275 85.41688766 84.63543526 - - 
360 - - 79.24206727 73.52470722 
540 - - 68.98591408 62.97892903 
720 - - 53.49474493 54.50450009 
900 - - 42.50004177 
 1260 49.05855521 54.14554024 
  1660 33.90527209 35.50132115 
  2800 0 0 
   















1 -0.013863736 -0.019684724 -0.071762038 -0.096316 
2 -0.00795523 -0.029870737 -0.068975489 -0.071379 
3 -0.013014089 -0.009168305 -0.056367313 -0.051371 
4 -0.047633303 -0.016363491 -0.054288537 -0.073022 
5 -0.016072551 -0.015010376 
  
6 -0.045746476 -0.017033163 
  






     Average -0.023213132 -0.017444684 -0.062848344 -0.073022 
STDEV 0.016352296 0.006180406 0.008799051 0.0183857 
 
Chart 5: Closure Rate Measurements for the HUVEC Culture Model 
 









1 -0.05224799 0.014101792 -0.070210305 -0.075337 
2 -0.037030271 -0.018881575 -0.046564877 -0.071748 
3 -0.038179228 -0.029585663 -0.058070382 -0.058588 
4 -0.029723942 -0.028141292 -0.05500393 -0.058754 
5     -0.068119618 
 
     Average -0.039295358 -0.015626684 -0.059593823 -0.066107 
STDEV 0.009412032 0.020378462 0.009728056 0.0087104 
 






 Wound Closure Rate Statistics: 
F-Test Two-Sample for Variances 
Huvec Control Vs. Huvec VitaSol 






Variance 0.0002674 3.82E-05 
Observations 7 8 
df 6 7 
F 7.000409 
 P(F<=f) one-tail 0.0107815 
 F Critical one-tail 3.8659689   
P<0.05 so assume unequal variance 
 
    
t-Test: Two-Sample Assuming Unequal Variances 
Huvec Control Vs. Huvec VitaSol 






Variance 0.0002674 3.82E-05 
Observations 7 8 
Hypothesized Mean Difference 0 





 P(T<=t) one-tail 0.2040411 
 t Critical one-tail 1.8945786 
 P(T<=t) two-tail 0.4080822 
 t Critical two-tail 2.3646243   
P>0.05 so there is no significant difference between 
groups 
Table 1: Statistical Table Huvec Control Vs. Huvec VitaSol 
 
F-Test Two-Sample for Variances 
Huvec Control Vs. Huvec Flow 
  Variable 1 Variable 2 
Mean -0.0232131 -0.0628483 
Variance 0.0002674 7.742E-05 
Observations 7 4 
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df 6 3 
F 3.4537096 
 P(F<=f) one-tail 0.1682448 
 F Critical one-tail 8.9406451   
P>0.05 so assume equal variance 
    
  t-Test: Two-Sample Assuming Equal Variances 
Huvec Control Vs. Huvec Flow 
  Variable 1 Variable 2 
Mean -0.0232131 -0.0628483 
Variance 0.0002674 7.742E-05 
Observations 7 4 
Pooled Variance 0.0002041 
 Hypothesized Mean Difference 0 
 df 9 
 t Stat 4.4266102 
 P(T<=t) one-tail 0.0008276 
 t Critical one-tail 1.8331129 
 P(T<=t) two-tail 0.0016553 
 t Critical two-tail 2.2621572   
P<0.05 so there is a statistically significant difference between 
groups 
Table 2: Statistical Table Huvec Control Vs. Huvec Flow 
 
F-Test Two-Sample for Variances 
 Huvec VitaSol Vs. Huvec Flow 




Variance 3.81974E-05 7.74233E-05 
Observations 8 4 
df 7 3 
F 0.49335826 
 P(F<=f) one-tail 0.198800536 
 F Critical one-tail 0.230052631   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
Huvec VitaSol Vs. Huvec Flow 
   Variable 1 Variable 2 




Variance 3.81974E-05 7.74233E-05 
Observations 8 4 
Pooled Variance 4.99652E-05 
 Hypothesized Mean Difference 0 
 df 10 
 t Stat 10.48917868 
 P(T<=t) one-tail 5.12156E-07 
 t Critical one-tail 1.812461102 
 P(T<=t) two-tail 1.02431E-06 
 t Critical two-tail 2.228138842   
P<0.05 so there is a statistically significant difference between 
groups 
Table 3: Statistical Table Huvec VitaSol Vs. Huvec Flow 
 
F-Test Two-Sample for Variances 
Huvec Control Vs. Huvec Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.02321 -0.07302 
Variance 0.000267 0.000338 
Observations 7 4 
df 6 3 
F 0.791034 
 P(F<=f) one-tail 0.367816 
 F Critical one-tail 0.210214   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
Huvec Control Vs. Huvec Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.02321 -0.07302 
Variance 0.000267 0.000338 
Observations 7 4 
Pooled Variance 0.000291 
 Hypothesized Mean Difference 0 
 df 9 
 t Stat 4.658913 
 P(T<=t) one-tail 0.000594 
 t Critical one-tail 1.833113 
 P(T<=t) two-tail 0.001187 
 t Critical two-tail 2.262157   
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P<0.05 so there is a statistically significant difference between 
groups 
Table 4: Statistical Table Huvec Control Vs. Huvec Flow VitaSol 
 
F-Test Two-Sample for Variances 
Huvec VitaSol Vs. Huvec Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.01744 -0.07302 
Variance 3.82E-05 0.000338 
Observations 8 4 
df 7 3 
F 0.112998 
 P(F<=f) one-tail 0.008839 
 F Critical one-tail 0.230053   
P<0.05 so assume unequal variance 
   t-Test: Two-Sample Assuming Unequal Variances 
Huvec VitaSol Vs. Huvec Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.01744 -0.07302 
Variance 3.82E-05 0.000338 
Observations 8 4 
Hypothesized Mean Difference 0 
 df 3 
 t Stat 5.881816 
 P(T<=t) one-tail 0.004903 
 t Critical one-tail 2.353363 
 P(T<=t) two-tail 0.009806 
 t Critical two-tail 3.182446   
P<0.05 so there is a statistically significant difference between 
groups 
Table 5: Statistical Table Huvec VitaSol Vs. Huvec Flow VitaSol 
 
F-Test Two-Sample for Variances 






Mean -0.06285 -0.07302 
Variance 7.74E-05 0.000338 
Observations 4 4 





P(F<=f) one-tail 0.128663 
 F Critical one-tail 0.107798   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean -0.06285 -0.07302 
Variance 7.74E-05 0.000338 
Observations 4 4 
Pooled Variance 0.000208 
 Hypothesized Mean Difference 0 
 df 6 
 t Stat 0.998255 
 P(T<=t) one-tail 0.178349 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.356697 
 t Critical two-tail 2.446912   
P>0.05 so there is no significant difference between 
groups 
Table 6: Statistical Table Huvec Flow Vs. Huvec Flow VitaSol 
 
F-Test Two-Sample for Variances 
 HDFa Control Vs. HDFa VitaSol 




Variance 8.85864E-05 0.000415282 
Observations 4 4 
df 3 3 
F 0.213316284 
 P(F<=f) one-tail 0.118324374 
 F Critical one-tail 0.107797789   
P>0.05 so assume equal variance   
      
t-Test: Two-Sample Assuming Equal Variances 
 HDFa Control Vs. HDFa VitaSol 




Variance 8.85864E-05 0.000415282 
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Observations 4 4 
Pooled Variance 0.000251934 
 Hypothesized Mean Difference 0 
 df 6 
 t Stat -2.1088491 
 P(T<=t) one-tail 0.039749589 
 t Critical one-tail 1.943180274 
 P(T<=t) two-tail 0.079499177 
 t Critical two-tail 2.446911846   
P>0.05 so there is no statistically significant difference between 
groups 
Table 7: Statistical Table HDFa Control Vs. HDFa VitaSol 
 
F-Test Two-Sample for Variances 
HDFa Control Vs. HDFa Flow 
  Variable 1 Variable 2 
Mean -0.0392954 -0.0595938 
Variance 8.859E-05 9.464E-05 
Observations 4 5 
df 3 4 
F 0.9360837 
 P(F<=f) one-tail 0.4983734 
 F Critical one-tail 0.109683   
P>0.05 so assume equal variance 
     
 t-Test: Two-Sample Assuming Equal Variances 
 HDFa Control Vs. HDFa Flow 
  Variable 1 Variable 2 
Mean -0.0392954 -0.0595938 
Variance 8.859E-05 9.464E-05 
Observations 4 5 
Pooled Variance 9.204E-05 
 Hypothesized Mean Difference 0 
 df 7 
 t Stat 3.154003 
 P(T<=t) one-tail 0.008031 
 t Critical one-tail 1.8945786 
 P(T<=t) two-tail 0.0160621 
 t Critical two-tail 2.3646243   
P<0.05 so there is a statistically significant difference between 
groups 




F-Test Two-Sample for Variances 
 HDFa VitaSol Vs. HDFa Flow 




Variance 0.000415282 9.46351E-05 
Observations 4 5 
df 3 4 
F 4.38824309 
 P(F<=f) one-tail 0.093531467 
 F Critical one-tail 6.591382117   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
 HDFa VitaSol Vs. HDFa Flow 




Variance 0.000415282 9.46351E-05 
Observations 4 5 
Pooled Variance 0.000232055 
 Hypothesized Mean Difference 0 
 df 7 
 t Stat 4.302554925 
 P(T<=t) one-tail 0.001777716 
 t Critical one-tail 1.894578604 
 P(T<=t) two-tail 0.003555432 
 t Critical two-tail 2.364624251   
P<0.05 so there is a statistically significant difference between 
groups 
Table 9: Statistical Table HDFa VitaSol Vs. HDFa Flow 
 
F-Test Two-Sample for Variances 
HDFa Control Vs. HDFa Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.0393 -0.06611 
Variance 8.86E-05 7.59E-05 
Observations 4 4 
df 3 3 
F 1.167591 




F Critical one-tail 9.276628   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
 HDFa Control Vs. HDFa Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.0393 -0.06611 
Variance 8.86E-05 7.59E-05 
Observations 4 4 
Pooled Variance 8.22E-05 
 Hypothesized Mean Difference 0 
 df 6 
 t Stat 4.181407 
 P(T<=t) one-tail 0.002902 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.005804 
 t Critical two-tail 2.446912   
P<0.05 so there is a statistically significant difference between 
groups 
Table 10: Statistical Table HDFa Control Vs. HDFa Flow VitaSol 
 
F-Test Two-Sample for Variances 
HDFa VitaSol Vs. HDFa Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.01563 -0.06611 
Variance 0.000415 7.59E-05 
Observations 4 4 
df 3 3 
F 5.473522 
 P(F<=f) one-tail 0.098154 
 F Critical one-tail 9.276628   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
 HDFa VitaSol Vs. HDFa Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.01563 -0.06611 
Variance 0.000415 7.59E-05 
Observations 4 4 
Pooled Variance 0.000246 





 t Stat 4.555557 
 P(T<=t) one-tail 0.001935 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.003869 
 t Critical two-tail 2.446912   
P<0.05 so there is a statistically significant difference between 
groups 
Table 11: Statistical Table HDFa VitaSol Vs. HDFa FlowVitaSol 
 
F-Test Two-Sample for Variances 
HDFa Flow Vs. HDFa Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.05959 -0.06611 
Variance 9.46E-05 7.59E-05 
Observations 5 4 
df 4 3 
F 1.247315 
 P(F<=f) one-tail 0.44565 
 F Critical one-tail 9.117182   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
 HDFa Flow Vs. HDFa Flow VitaSol 
  Variable 1 Variable 2 
Mean -0.05959 -0.06611 
Variance 9.46E-05 7.59E-05 
Observations 5 4 
Pooled Variance 8.66E-05 
 Hypothesized Mean Difference 0 
 df 7 
 t Stat 1.043342 
 P(T<=t) one-tail 0.165738 
 t Critical one-tail 1.894579 
 P(T<=t) two-tail 0.331477 
 t Critical two-tail 2.364624   
P>0.05 so there is no statistically significant difference between 
groups 
Table 12: Statistical Table HDFa Flow Vs. HDFa FlowVitaSol 
 
 MTT Assay Statistics: 




Huvec Control Vs. Huvec VitaSol 
 
  Variable 1 
Variable 
2 
Mean 0.0316 0.0319 
Variance 0.00000193 3E-06 
Observations 3 3 
df 2 2 
F 0.712177122 
 P(F<=f) one-tail 0.415948276 
 F Critical one-tail 0.052631579   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
 Huvec Control Vs. Huvec VitaSol 
 
  Variable 1 
Variable 
2 
Mean 0.0316 0.0319 
Variance 0.00000193 3E-06 
Observations 3 3 
Pooled Variance 0.00000232 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat -0.24122532 
 P(T<=t) one-tail 0.410620638 
 t Critical one-tail 2.131846782 
 P(T<=t) two-tail 0.821241275 
 t Critical two-tail 2.776445105   
P>0.05 so there is no significant difference between groups 
Table 13: Statistical Table Huvec Control Vs. Huvec VitaSol 
 
F-Test Two-Sample for Variances 
Huvec Control Vs. Huvec Flow 
  Variable 1 Variable 2 
Mean 0.0316 0.032766667 
Variance 0.00000193 1.34333E-06 
Observations 3 3 
df 2 2 
F 1.436724566 
 P(F<=f) one-tail 0.410386965 
 F Critical one-tail 19   





   t-Test: Two-Sample Assuming Equal Variances 
Huvec Control Vs. Huvec Flow 
  Variable 1 Variable 2 
Mean 0.0316 0.032766667 
Variance 0.00000193 1.34333E-06 
Observations 3 3 
Pooled Variance 1.63667E-06 
 Hypothesized Mean 
Difference 0 





 P(T<=t) one-tail 0.163298694 
 t Critical one-tail 2.131846782 
 P(T<=t) two-tail 0.326597388 
 t Critical two-tail 2.776445105   
P>0.05 so there is no significant difference between groups 
Table 14: Statistical Table Huvec Control Vs. Huvec Flow 
 
F-Test Two-Sample for Variances 






Mean 0.0316 0.032567 
Variance 1.93E-06 1.29E-06 
Observations 3 3 
df 2 2 
F 1.492268 
 P(F<=f) one-tail 0.401241 
 F Critical one-tail 19   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.0316 0.032567 
Variance 1.93E-06 1.29E-06 
Observations 3 3 




Hypothesized Mean Difference 0 
 df 4 
 t Stat -0.93258 
 P(T<=t) one-tail 0.201916 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.403831 
 t Critical two-tail 2.776445   
P>0.05 so there is no significant difference between 
groups 
Table 15: Statistical Table Huvec Control Vs. Huvec Flow VitaSol 
 
F-Test Two-Sample for Variances 






Mean 0.0319 0.032767 
Variance 2.71E-06 1.34E-06 
Observations 3 3 
df 2 2 
F 2.01737 
 P(F<=f) one-tail 0.331414 
 F Critical one-tail 19   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.0319 0.032767 
Variance 2.71E-06 1.34E-06 
Observations 3 3 
Pooled Variance 2.03E-06 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat -0.7456 
 P(T<=t) one-tail 0.248669 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.497338 
 t Critical two-tail 2.776445   
P>0.05 so there is no significant difference between 
groups 
Table 16: Statistical Table Huvec VitaSol Vs. Huvec Flow 
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F-Test Two-Sample for Variances 






Mean 0.0319 0.032567 
Variance 2.71E-06 1.29E-06 
Observations 3 3 
df 2 2 
F 2.095361 
 P(F<=f) one-tail 0.323064 
 F Critical one-tail 19   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.0319 0.032567 
Variance 2.71E-06 1.29E-06 
Observations 3 3 
Pooled Variance 2E-06 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat -0.57711 
 P(T<=t) one-tail 0.297395 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.59479 
 t Critical two-tail 2.776445   
P>0.05 so there is no significant difference between 
groups 
Table 17: Statistical Table Huvec VitaSol Vs. Huvec Flow VitaSol 
 
F-Test Two-Sample for Variances 






Mean 0.032767 0.032567 
Variance 1.34E-06 1.29E-06 
Observations 3 3 
df 2 2 
F 1.03866 




F Critical one-tail 19   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.032767 0.032567 
Variance 1.34E-06 1.29E-06 
Observations 3 3 
Pooled Variance 1.32E-06 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat 0.213335 
 P(T<=t) one-tail 0.420749 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.841498 
 t Critical two-tail 2.776445   
P>0.05 so there is no significant difference between 
groups 
Table 18: Statistical Table Huvec Flow Vs. Huvec Flow VitaSol 
 
F-Test Two-Sample for Variances 
 HDFa Control Vs. HDFa VitaSol 
  
  Variable 1 
Variable 
2 
Mean 0.031133333 0.0317 
Variance 9.43333E-07 2E-06 
Observations 3 3 
df 2 2 
F 0.43404908 
 P(F<=f) one-tail 0.302673797 
 F Critical one-tail 0.052631579   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
 HDFa Control Vs. HDFa VitaSol 
  
  Variable 1 
Variable 
2 
Mean 0.031133333 0.0317 
Variance 9.43333E-07 2E-06 
Observations 3 3 
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Pooled Variance 1.55833E-06 
 Hypothesized Mean Difference 0 





 P(T<=t) one-tail 0.314222195 
 t Critical one-tail 2.131846782 
 P(T<=t) two-tail 0.628444391 
 t Critical two-tail 2.776445105   
P>0.05 so there is no significant difference between groups 
Table 19: Statistical Table HDFa Control Vs. HDFa VitaSol 
 
F-Test Two-Sample for Variances 
HDFa Control Vs. HDFa Flow 
   Variable 1 Variable 2 
Mean 0.031133333 0.032466667 
Variance 9.43333E-07 1.26333E-06 
Observations 3 3 
df 2 2 
F 0.746701847 
 P(F<=f) one-tail 0.427492447 
 F Critical one-tail 0.052631579   
P>0.05 so assume equal 
variance 
  
   t-Test: Two-Sample Assuming Equal Variances 
HDFa Control Vs. HDFa Flow 
   Variable 1 Variable 2 
Mean 0.031133333 0.032466667 
Variance 9.43333E-07 1.26333E-06 
Observations 3 3 
Pooled Variance 1.10333E-06 
 Hypothesized Mean 
Difference 0 





 P(T<=t) one-tail 0.09750143 
 t Critical one-tail 2.131846782 
 P(T<=t) two-tail 0.195002861 
 t Critical two-tail 2.776445105   
P>0.05 so there is no significant difference between groups 
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Table 20: Statistical Table HDFa Control Vs. HDFa Flow 
 
F-Test Two-Sample for Variances 






Mean 0.031133 0.0327 
Variance 9.43E-07 1.72E-06 
Observations 3 3 
df 2 2 
F 0.54845 
 P(F<=f) one-tail 0.354193 
 F Critical one-tail 0.052632   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.031133 0.0327 
Variance 9.43E-07 1.72E-06 
Observations 3 3 
Pooled Variance 1.33E-06 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat -1.66274 
 P(T<=t) one-tail 0.085849 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.171699 
 t Critical two-tail 2.776445   
P>0.05 so there is no significant difference between 
groups 
Table 21: Statistical Table HDFa Control Vs. HDFa Flow VitaSol 
 
F-Test Two-Sample for Variances 






Mean 0.031667 0.032467 
Variance 2.17E-06 1.26E-06 
Observations 3 3 




 P(F<=f) one-tail 0.367604 
 F Critical one-tail 19   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.031667 0.032467 
Variance 2.17E-06 1.26E-06 
Observations 3 3 
Pooled Variance 1.72E-06 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat -0.74745 
 P(T<=t) one-tail 0.248169 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.496337 
 t Critical two-tail 2.776445   
P>0.05 so there is no significant difference between 
groups 
Table 22: Statistical Table HDFa VitaSol Vs. HDFa Flow 
 
F-Test Two-Sample for Variances 






Mean 0.031667 0.0327 
Variance 2.17E-06 1.72E-06 
Observations 3 3 
df 2 2 
F 1.263566 
 P(F<=f) one-tail 0.441781 
 F Critical one-tail 19   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.031667 0.0327 
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Variance 2.17E-06 1.72E-06 
Observations 3 3 
Pooled Variance 1.95E-06 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat -0.90707 
 P(T<=t) one-tail 0.207837 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.415673 
 t Critical two-tail 2.776445   
P>0.05 so there is no significant difference between 
groups 
Table 23: Statistical Table HDFa VitaSol Vs. HDFa Flow VitaSol 
 
F-Test Two-Sample for Variances 






Mean 0.032467 0.0327 
Variance 1.26E-06 1.72E-06 
Observations 3 3 
df 2 2 
F 0.734496 
 P(F<=f) one-tail 0.423464 
 F Critical one-tail 0.052632   
P>0.05 so assume equal variance 
  
   t-Test: Two-Sample Assuming Equal Variances 






Mean 0.032467 0.0327 
Variance 1.26E-06 1.72E-06 
Observations 3 3 
Pooled Variance 1.49E-06 
 Hypothesized Mean Difference 0 
 df 4 
 t Stat -0.23398 
 P(T<=t) one-tail 0.413243 
 t Critical one-tail 2.131847 
 P(T<=t) two-tail 0.826485 
 t Critical two-tail 2.776445   
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P>0.05 so there is no significant difference between 
groups 




Appendix III: Representative Photos From Each Testing Group 
HUVEC Control Initial: 




HUVEC Control Final: 




HUVEC VitaSol Intermediate: 
 




HUVEC Flow Initial: 
 




HUVEC Flow Final: 
 




HUVEC Flow VitaSol Intermediate: 
 





HDFa Control Initial: 
 




HDFa Control Final: 
 




HDFa VitaSol Intermediate: 
 




HDFa Flow Initial: 
 




HDFa Flow Final: 
 




HDFa Flow VitaSol Intermediate: 
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